UPDATE: Intra-Cellular Therapies stock soars 83% premarket after FDA approves schizophrenia treatment
Intra-Cellular Therapies Inc. shares soared 83% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved a treatment for schizophrenia in adults. The New York-based biotech said the approval of its caplyta drug comes after two trials that showed a statistically significant separation from placebo. The company is expecting to start sales of the drug late in the first quarter of 2020. Schizophrenia is a serious mental illness that affects about 2.4 million adults in the U.S. and can cause such symptoms as hallucinations, delusions and psychosis. Intra-Cellular Therapies shares have gained 9% in 2019 through Friday, while the S&P 500 has gained 28.5%.
Source : MTV
